

# Etriam®

Econazole Nitrate BP and Triamcinolone  
Acetonide BP Cream

## DESCRIPTION

**Etriam®** is a combined preparation of Econazole Nitrate & Triamcinolone Acetonide. Econazole nitrate is a triazole fungicide, designated chemical. A broad spectrum of antimycotic activity has been demonstrated against dermatophytes, yeasts and molds. A clinically relevant action against gram positive bacteria has also been found. Econazole nitrate acts by damaging cell membranes. Triamcinolone acetonide is a fluorinated corticosteroid. Triamcinolone acetonide is a more potent form of the naturally-occurring adrenocortical hormone. The mechanism of anti-inflammatory activity of the corticosteroids is unclear, but there is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in human.

## INDICATIONS

**Etriam®** Cream is indicated for the treatment of skin infections caused by dermatophytes or *Candida spp.*, in which inflammatory symptoms are prominent.

## DOSAGE AND ADMINISTRATION

Apply sparingly to the skin lesion no more than 2 times daily, preferably once in the morning and once in the evening. **Etriam®** Cream should not be applied with an occlusive dressing, or to large areas of skin on the body. The duration of treatment should continue until the inflammatory symptoms subside but not longer than 2 weeks; after 2 weeks of therapy with **Etriam®** Cream, continue therapy as needed with a preparation containing Econazole or Econazole nitrate alone.

## CONTRAINDICATIONS

**Etriam®** Cream is contraindicated in individuals who have shown hypersensitivity to any API of this product. Like any other dermatological preparation containing corticosteroids, **Etriam®** Cream is contraindicated in specific skin conditions such as tuberculous, varicella, herpes simplex or other viral infections of the skin, or fresh vaccination sites.

## SIDE EFFECTS

- Skin burning sensation
- Skin irritation
- Erythema

## WARNINGS AND PRECAUTIONS

For external use only. **Etriam®** Cream is not for ophthalmic or oral use. If a reaction suggesting hypersensitivity or chemical irritation should occur, use of the medication should be discontinued. Corticosteroids applied to the skin can be absorbed in sufficient amounts to produce systemic effects, including adrenal suppression. Systemic absorption may be increased by various factors such as application over a large skin surface area, application to damaged skin, application under occlusive skin dressings and prolonged duration of therapy.

## USE IN PREGNANCY AND LACTATION

There are no adequate and well-controlled studies on adverse effects from the use of **Etriam®** Cream in pregnant women, and no other relevant epidemiological data are available. No adverse effects on pregnancy or on the health of the foetus/ newborn child have been identified from a limited number of post-marketing reports.

There are no adequate and well-controlled studies on the topical administration of **Etriam®** Cream during lactation. It is not known whether concomitant topical administration of **Etriam®** Cream to the skin could result in sufficient systemic absorption to produce detectable quantities in breast milk in humans. Caution should be exercised when **Etriam®** Cream is administered to nursing mothers.

## PHARMACEUTICAL PRECAUTIONS

Keep away from light and wet place. Keep out of reach of children.

## PACKAGING

**Etriam®** Cream: Tube containing 10 gram of cream. Each gram cream contains Econazole Nitrate BP 10 mg and Triamcinolone Acetonide BP 1 mg.

**SK•F**

Manufactured by  
**ESKAYEF PHARMACEUTICALS LTD.**  
GAZIPUR, BANGLADESH  
© REGD. TRADEMARK  
PM05855 V01